Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01859819 · ClinicalTrials.gov registry record · Phase 2
Treatment for Advanced B-Cell Lymphoma
A Phase 2 study, sponsored by New York Medical College.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT01859819 is a Phase 2 study that has completed, run by New York Medical College. The registered enrollment target is 45 participants.
The verdict
NCT01859819, a Phase 2 study, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
To safely reduce the burden of therapy in children, adolescents and young adults with mature B-NHL by reducing the number of intrathecal (IT) injections by the introduction of IT Liposomal Cytarabine (L-ARA-C, \[Depocyt®\]) and reducing the dose of anthracycline (doxorubicin) in good risk patients with the addition of rituximab to the FAB chemotherapy backbone (Immunochemotherapy).
Interventions
- DRUG Rituximab
- DRUG IT Cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2013-01 |
| Est. Completion | 2021-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01859819
The ClinicalTrials.gov registry entry for NCT01859819 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT01859819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01859819 about?
NCT01859819 is a clinical study titled "Treatment for Advanced B-Cell Lymphoma". To safely reduce the burden of therapy in children, adolescents and young adults with mature B-NHL by reducing the number of intrathecal (IT) injections by the introduction of IT Liposomal Cytarabine (L-ARA-C, \[Depocyt®\]) and reducing the dose of anthracycline (doxorubicin) in good risk patients w...
What is the current status of trial NCT01859819?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2013-01. Estimated completion is 2021-06.
What interventions are being tested in trial NCT01859819?
The interventions under investigation include: Rituximab (DRUG), IT Cytarabine (DRUG).
Who is sponsoring clinical trial NCT01859819?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.